News

Biogen Appoints Tim Power as Head of Investor Relations

“LEQEMBI®” (Lecanemab) Approved for the Treatment of Early Alzheimer’s Disease in Mexico

“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in South Korea

Biogen to Participate in the 7th Annual Evercore HealthCONx Conference

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Biogen Reports Third Quarter 2024 Results